171 related articles for article (PubMed ID: 37431726)
1. An update on understanding the pathophysiology in Kawasaki disease: Possible role of immune complexes in coronary artery lesion revisited.
Philip S; Jindal A; Krishna Kumar R
Int J Rheum Dis; 2023 Aug; 26(8):1453-1463. PubMed ID: 37431726
[TBL] [Abstract][Full Text] [Related]
2. Role of Antioxidants in Horse Serum-mediated Vasculitis in Swine: Potential Relevance to Early Treatment in Mitigation of Coronary Arteritis in Kawasaki Disease.
Philip S; Lee WC; Cherian KM; Wu MH; Lue HC
Pediatr Neonatol; 2017 Aug; 58(4):328-337. PubMed ID: 28209472
[TBL] [Abstract][Full Text] [Related]
3. Histopathological evaluation of horse serum-induced immune complex vasculitis in swine: implication to coronary artery lesions in Kawasaki disease.
Philip S; Lee WC; Wu MH; Mammen CK; Lue HC
Pediatr Neonatol; 2014 Aug; 55(4):297-305. PubMed ID: 24491664
[TBL] [Abstract][Full Text] [Related]
4. [Matrix metalloproteinase-1 expression in the circulation of patients with Kawasaki disease and its role in the pathogenesis of coronary artery lesions].
Yang SW; Wang DW; Li J; Qin YM; Wang FM; Cao LM; Zhang LF; Hu Z
Zhonghua Er Ke Za Zhi; 2005 Aug; 43(8):612-5. PubMed ID: 16191276
[TBL] [Abstract][Full Text] [Related]
5. Kawasaki Disease: The Role of Immune Complexes Revisited.
Menikou S; Langford PR; Levin M
Front Immunol; 2019; 10():1156. PubMed ID: 31263461
[TBL] [Abstract][Full Text] [Related]
6. The relationship between TNF-like protein 1A and coronary artery aneurysms in children with Kawasaki disease.
Zhang J; Weng H; Pei Q; Yang P; Fan W; Liu R; Yi Q
Clin Exp Med; 2022 Feb; 22(1):57-63. PubMed ID: 34232416
[TBL] [Abstract][Full Text] [Related]
7. Kawasaki disease: basic and pathological findings.
Takahashi K; Oharaseki T; Yokouchi Y; Naoe S; Saji T
Clin Exp Nephrol; 2013 Oct; 17(5):690-693. PubMed ID: 23188196
[TBL] [Abstract][Full Text] [Related]
8. Cytokine cascade in Kawasaki disease versus Kawasaki-like syndrome.
Bordea MA; Costache C; Grama A; Florian AI; Lupan I; Samasca G; Deleanu D; Makovicky P; Makovicky P; Rimarova K
Physiol Res; 2022 Mar; 71(1):17-27. PubMed ID: 35043641
[TBL] [Abstract][Full Text] [Related]
9. A Comprehensive Update on Kawasaki Disease Vasculitis and Myocarditis.
Soni PR; Noval Rivas M; Arditi M
Curr Rheumatol Rep; 2020 Feb; 22(2):6. PubMed ID: 32020498
[TBL] [Abstract][Full Text] [Related]
10. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).
Tremoulet AH; Jain S; Kim S; Newburger J; Arditi M; Franco A; Best B; Burns JC
Contemp Clin Trials; 2016 May; 48():70-5. PubMed ID: 27080929
[TBL] [Abstract][Full Text] [Related]
11. Preventing coronary artery lesions in Kawasaki disease.
Kuo HC
Biomed J; 2017 Jun; 40(3):141-146. PubMed ID: 28651735
[TBL] [Abstract][Full Text] [Related]
12. Kawasaki disease: a comprehensive review of treatment options.
Patel RM; Shulman ST
J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
[TBL] [Abstract][Full Text] [Related]
13. A framework for understanding Kawasaki disease pathogenesis.
Lo MS
Clin Immunol; 2020 May; 214():108385. PubMed ID: 32173601
[TBL] [Abstract][Full Text] [Related]
14. Decreased serum Annexin A1 levels in Kawasaki disease with coronary artery aneurysm.
Weng H; Peng Y; Pei Q; Jing F; Yang M; Yi Q
Pediatr Res; 2021 Feb; 89(3):569-573. PubMed ID: 32316027
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm.
Wu Y; Liu FF; Xu Y; Wang JJ; Samadli S; Wu YF; Liu HH; Chen WX; Luo HH; Zhang DD; Wei W; Hu P
Clin Exp Med; 2019 May; 19(2):173-181. PubMed ID: 30617865
[TBL] [Abstract][Full Text] [Related]
16. Dissecting Kawasaki disease: a state-of-the-art review.
Dietz SM; van Stijn D; Burgner D; Levin M; Kuipers IM; Hutten BA; Kuijpers TW
Eur J Pediatr; 2017 Aug; 176(8):995-1009. PubMed ID: 28656474
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of anti-apolipoprotein A-2 on an animal model for coronary arteritis in Kawasaki disease.
Ito F; Oharaseki T; Tsukui D; Kimura Y; Yanagida T; Kishi F; Yamakawa Y; Kameoka Y; Suzuki S; Uno K; Suzuki O; Miura NN; Ohno N; Takahashi K; Kono H; Suzuki K
Pediatr Rheumatol Online J; 2022 Dec; 20(1):119. PubMed ID: 36550471
[TBL] [Abstract][Full Text] [Related]
18. Prednisolone Suppresses the Extracellular Release of HMGB-1 and Associated Inflammatory Pathways in Kawasaki Disease.
Ueno K; Nomura Y; Morita Y; Kawano Y
Front Immunol; 2021; 12():640315. PubMed ID: 34079539
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of HMGB1-RAGE in Kawasaki disease with coronary artery injury.
Qian B; Huang H; Cheng M; Qin T; Chen T; Zhao J
Eur J Med Res; 2020 Mar; 25(1):8. PubMed ID: 32183905
[TBL] [Abstract][Full Text] [Related]
20. Histopathological aspects of cardiovascular lesions in Kawasaki disease.
Takahashi K; Oharaseki T; Yokouchi Y
Int J Rheum Dis; 2018 Jan; 21(1):31-35. PubMed ID: 29105353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
